

Amendment to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

In the claims:

Claim 1-3 (Canceled).

Claim 4 (Currently Amended) A composition comprising five meningococcal antigens: (1) a 'NadA' protein or a variant thereof; (2) a 'NMB1870' protein or a variant thereof; (3) a 'NMB2091' protein or a variant thereof; (4) a 'NMB1030' protein or a variant thereof; and (5) a 'NMB2132' protein or a variant thereof, wherein the composition after administration to a mammalian subject is able to induce an antibody response in that subject, wherein the antibody response is bactericidal against a strain from each of hypervirulent lineages A4, ET-5 and lineage 3 of N.meningitidis serogroup B.

Claim 5 (Canceled).

Claim 6 (Previously Presented) The composition of claim 4, wherein the NadA protein comprises SEQ ID 2.

Claim 7 (Canceled).

Claim 8 (Previously Presented) The composition of claim 4 , wherein the NMB1870 protein comprises SEQ ID 3.

Claim 9 (Canceled).

Claim 10 (Previously Presented) The composition of claim 4 , wherein the NMB2091 protein comprises SEQ ID 4.

Claim 11 (Canceled).

Claim 12 (Previously Presented) The composition of claim 4, wherein NMB1030 protein comprises SEQ ID 5.

Claim 13 (Canceled).

Claim 14 (Previously Presented) The composition of claim 4, wherein the NMB2132 protein comprises SEQ ID 6.

Claim 15 (Withdrawn) The composition of claim 4, wherein at least two of the antigens (1) to (5) are expressed as a single polypeptide chain.

Claim 16 (Withdrawn) The composition of claim 4, wherein the two recombinant polypeptides are expressed as a single polypeptide chain and are selected from the group of antigens consisting of: a 'NadA' protein & a 'NMB1870' protein; the 'NadA' protein & a 'NMB2091' protein; the 'NadA' protein & a 'NMB1030' protein; the 'NadA' protein & a 'NMB2132' protein; the 'NMB1870' protein & the 'NMB2091' protein; the 'NMB1870' protein & the 'NMB1030' protein; the 'NMB1870' protein & the 'NMB2132' protein; the 'NMB2091' protein & the 'NMB1030' protein; the 'NMB2091' protein & the 'NMB2132' protein; the 'NMB1030' protein & the 'NMB2132' protein.

Claim 17 (Withdrawn) The composition of claims 15 or 16, wherein the single polypeptide chain comprises a polypeptide of formula $\text{NH}_2\text{-A-X}_1\text{-L-X}_2\text{-B-COOH}$, wherein: X_1 is an amino acid sequence of one of the five antigens selected from the group consisting of the 'NadA' protein, the 'NMB1870' protein; the 'NMB2091' protein; the 'NMB1030' protein; and the 'NMB2132' protein ; X_2 is an amino acid sequence of one of the five antigens selected from the group consisting of the 'NadA' protein, the 'NMB1870' protein; the 'NMB2091' protein; the 'NMB1030' protein; and the 'NMB2132' protein provided that X_1 is not the same as X_2 ; L is an optional linker amino acid sequence; A is an optional N-terminal amino acid sequence; and B is an optional C-terminal amino acid sequence.

Claim 18 (Withdrawn) The composition of claim 17, wherein X_1 is the NMB2091 protein and X_2 is the NMB1870 protein.

Claim 19 (Withdrawn) The composition of claim 17, wherein X_1 is the NMB2132 protein and X_2 is the NMB1030 protein.

Claims 20-21 (Canceled).

Claim 22 (Withdrawn) The composition of claim 4, further comprising saccharide antigens from meningococcus serogroups Y, W135, C and (optionally) A.

Claim 23 (Withdrawn) The composition of claim 4, further comprising a saccharide antigen from *Haemophilus influenzae* type B.

Claim 24 (Withdrawn) The composition of claim 22 or claim 23, wherein the saccharide antigen is conjugated to a carrier selected from: diphtheria toxoid, tetanus toxoid, CRM₁₉₇ or *H.influenzae* protein D.

Claim 25 (Withdrawn) The composition of claim 4, further comprising an antigen from *Streptococcus pneumoniae*.

Claim 26 (Previously Presented) The composition of claim 4 further comprising a pharmaceutically acceptable carrier.

Claim 27 (Canceled).

Claim 28 (Withdrawn) A method for raising an antibody response in a mammal, comprising the step of administering an effective amount of a composition according to any one of claims 4, 15, or 16.

Claims 29-31 (Canceled).

Claim 32 (New) The composition of claim 4, wherein the NadA protein comprises an amino acid sequence having at least 90% sequence identity to SEQ ID 2, wherein the NMB1870 protein comprises an amino acid sequence having at least 90% sequence identity to SEQ ID 3, wherein the NMB2091 protein comprises an amino acid sequence having at least 90% sequence identity to SEQ

ID 4, wherein NMB1030 protein comprises an amino acid sequence having at least 90% sequence identity to SEQ ID 5, and wherein the NMB2132 protein comprises an amino acid sequence having at least 90% sequence identity to SEQ ID 6.

Claim 33 (New) The composition of claim 4, wherein the NadA protein comprises an amino acid sequence having at least 95% sequence identity to SEQ ID 2, wherein the NMB1870 protein comprises an amino acid sequence having at least 95% sequence identity to SEQ ID 3, and wherein the NMB2091 protein comprises an amino acid sequence having at least 95% sequence identity to SEQ ID 4, wherein NMB1030 protein comprises an amino acid sequence having at least 95% sequence identity to SEQ ID 5, and wherein the NMB2132 protein comprises an amino acid sequence having at least 95% sequence identity to SEQ ID 6.

Claim 34 (New) The composition of claim 4, wherein the NadA protein comprises SEQ ID 2, wherein the NMB1870 protein comprises SEQ ID 3, and wherein the NMB2091 protein comprises SEQ ID 4, wherein NMB1030 protein comprises SEQ ID 5, and wherein the NMB2132 protein comprises SEQ ID 6.